The Food and Drug Administration issued a partial clinical hold on new enrollments for Epizyme Inc.'s (Nasdaq: EPZM) tazemetostat clinical trials sending the stock price plummeting $2.30 to close at $13.00.
Partial clinical hold on Epizyme's new enrollments
April 24, 2018 at 18:02 PM EDT
